Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
June 18, 2018 (Issue: 1549)
The FDA has approved a fixed-dose combination of
meropenem, a carbapenem antibiotic, and vaborbactam,
a new beta-lactamase inhibitor (Vabomere – Melinta),
for IV treatment of adults with complicated urinary
tract infections (UTIs) that are...more
- Ceftazidime/avibactam (Avycaz) – a new intravenous antibiotic. Med Lett Drugs Ther 2015; 57:79.
- J Rodriguez-Baño et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 2018; 31:e00079.
- O Lomovskaya et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61:e01443.
- M Castanheira et al. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61:e00567.
- MA Pfaller et al. In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. Int J Antimicrob Agents 2018 March 3 (epub).
- KS Kaye et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA 2018; 319:788.
- KS Kaye et al. Clinical outcomes of serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) in TANGO II, a phase 3, randomized, multi-national, open-label trial of meropenem-vaborbactam (M-V) versus best available therapy (BAT). Open Forum Infect Dis 2017; 4 (suppl 1):S534.10. Abstract 1862.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2018. Reprinted with permission by First Databank, Inc. All rights reserved. ©2018. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
Article code: 1549c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
